Yiling Pharmaceutical's depression-resolving and restlessness-relieving capsules have been approved for marketing via the obtained Drug Registration Certificate issued by China's National Medical Products Administration (NMPA). The company owns the full intellectual property rights of the drug.
The drug is an innovative traditional Chinese medicine (TCM) independently developed by Yiling Pharmaceutical based on clinical practices, applicable to mild and moderate depression with symptoms of moodiness, dysphoria, loss of appetite, insomnia and dreaminess, dizziness and tinnitus, etc.
A multicenter, randomized, double-blind, double-simulated, placebo-fluoxetine hydrochloride tablet controlled clinical trial has been conducted for the drug.
It is reported that 11 new TCMs have been approved in China this year, a new high in recent years, and the two innovative patent TCMs of "Depression-resolving and Restlessness-relieving Capsules" and "Kidney-tonifying and Heart-nourishing Tranquilization Tablets" developed by Yiling Pharmaceutical are in the list.
